What is brigatinib?

Brigatinib (Brigatinib) is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC), especially patients with anaplastic lymphoma kinase (ALK)-positive mutations. Brigatinib (Brigatinib) was developed by ARIC Pharmaceuticals and was approved by the U.S. Food and Drug Administration (FDA) in 2017. Its development and use represent an innovative treatment option for patients with ALK-positive NSCLC.

Brigatinib (Brigatinib) is a tyrosine kinase inhibitor (TKI). Its main mechanism of action is to prevent the growth and spread of cancer cells by inhibiting the activity of the ALK gene. In addition to ALK, brigatinib inhibits several other cancer-related enzymes, such as ROS1 and EGFR. This multi-target inhibitory effect makesBrigatinib show remarkable results in the treatment ofALKpositiveNSCLC effective, especially in cases of resistance to other ALK inhibitors such as crizotinib (Crizotinib).

Clinical trials have shown that brigatinib (Brigatinib) has a higher response rate and longer progression-free survival in the treatment of ALKpositive NSCLC patients. Particularly for patients who have failed treatment with other ALK inhibitors such as crizotinib, brigatinib (brigatinib) offers an effective alternative. Its multi-target inhibitory properties enable it to demonstrate good therapeutic effects in a variety of conditions and significantly improve patients' quality of life.

Although brigatinib in the treatmentALKPositiveNSCLC performs well, but it may also cause a series of adverse reactions. Common adverse reactions include interstitial lung disease (ILD), hypertension, visual impairment, bradycardia and gastrointestinal reactions. Patients should undergo regular medical examinations during the use of brigatinib (brigatinib) to monitor the efficacy and side effects of the drug, and adjust the treatment plan according to the specific situation. Regular medical examinations and doctor's guidance can help patients better manage various challenges during treatment and ensure optimal treatment effects and safety.